The presentation will be delivered by Ryan Sullivan, M.D., Assistant Professor, Medicine, Harvard Medical School and Assistant Professor, Hematology/Oncology, Massachusetts General Hospital.
The presentation will be made available on the Compugen website at www.cgen.com following the conclusion of the presentation.
Compugen is a clinical-stage therapeutic discovery and development company. This firm utilizes its broadly applicable, predictive computational discovery platforms to identify drug targets and develop therapeutics in the field of cancer immunotherapy.
- COM701: This antibody is the lead Compugen product candidate. It is a first-in-class anti-PVRIG antibody for the treatment of solid tumors undergoing a Phase 1 clinical study. COM701 is a humanized antibody that binds with a high affinity to PVRIG, a novel immune checkpoint discovered computationally by Compugen. The antibody blocks the interaction with its ligand, PVRL2.
PVRIG constitute parallel immune checkpoint pathways that counteract DNAM, a costimulatory molecule on T cells and NK cells.
Preclinical data suggest that the blockade of PVRIG induces a robust anti-tumor immune response and demonstrates synergistic activity when used in combination with inhibitors of TIGIT and/or PD-1. Currently, COM701 is being evaluated in the Phase 1 clinical study.
Data from the ongoing study have shown that COM701 is well-tolerated and demonstrated preliminary signs of anti-tumor activity in a heavily pretreated patient population.
- COM902: This Compugen antibody targets TIGIT that was also discovered by Compugen’s computational discovery platform in 2009. The product is also in the Phase 1 clinical study.
The Company’s pipeline products also include early-stage immuno-oncology programs focused largely on myeloid targets.
Compugen’s business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with offices in South San Francisco, CA.
Compugen might be a small firm but its predictive computational discovery platform has shown an awesome capability in discovering new targets for cancer immunotherapy. The immune checkpoint inhibitor COM701 is created by Compugen and the immune checkpoint PVRIG is discovered computationally by Compugen.
As we have stated in our series “An Evaluation of Biotech Firms“, it is impossible to evaluate biotechnology firms without assessing their scientific and technological capabilities and the promises of their pipeline products.
We are impatiently waiting to hear more details about the good news during Compugen’s presentation at the 2020 AACR Annual Meeting on April 27, 2020, at 11:45 a.m. EST.
To read more about this firm please use the search engine at our website.
Compugen: A Small Firm with Giant Technological Capabilities
Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting
Compugen (CGEN) announced that it will present updates on its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG for the treatment of advanced solid tumors, in an oral presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I on April 27, 2020 at 11:45 a.m. EST.
The presentation titled, “COM701 demonstrates preliminary antitumor activity as monotherapy and in combination with nivolumab in patients with advanced solid tumors”, will include updates from the dose-escalation arms of COM701 monotherapy and in combination with nivolumab.